Unknown

Dataset Information

0

N-terminus of flagellin enhances vaccine efficacy against Actinobacillus pleuropneumoniae.


ABSTRACT:

Background

Flagellin elicits potent immune response and may serve as a vaccine adjuvant. We previously reported that the N-terminus of flagellin (residues 1-99, nFliC) is sufficient for vaccine efficacy enhancement against Pasteurella multocida challenge in chickens. In this study, we futher tested the adjuvancy of nFliC in a subunit vaccine against the pig pathogen Actinobacillus pleuropneumoniae in a mice model. For vaccine formulation, the antigen ApxIIPF (the pore-forming region of the exotoxin ApxII) was combined with nFliC, either through genetic fusion or simple admixture.

Results

Immune analysis showed that nFliC, introduced through genetic fusion or admixture, enhanced both humoral (antibody levels) and cellular (T cell response and cytokine production) immunity. In a challenge test, nFliC increased vaccine protective efficacy to 60-80%, vs. 20% for the antigen-only group. Further analysis showed that, even without a supplemental adjuvant such as mineral salt or oil emulsion, genetically linked nFliC still provided significant immune enhancement.

Conclusions

We conclude that nFliC is a versatile and potent adjuvant for vaccine formulation.

SUBMITTER: Chuekwon K 

PROVIDER: S-EPMC9288005 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

N-terminus of flagellin enhances vaccine efficacy against Actinobacillus pleuropneumoniae.

Chuekwon Kamonpun K   Chu Chun-Yen CY   Cheng Li-Ting LT  

BMC veterinary research 20220716 1


<h4>Background</h4>Flagellin elicits potent immune response and may serve as a vaccine adjuvant. We previously reported that the N-terminus of flagellin (residues 1-99, nFliC) is sufficient for vaccine efficacy enhancement against Pasteurella multocida challenge in chickens. In this study, we futher tested the adjuvancy of nFliC in a subunit vaccine against the pig pathogen Actinobacillus pleuropneumoniae in a mice model. For vaccine formulation, the antigen ApxIIPF (the pore-forming region of t  ...[more]

Similar Datasets

| S-EPMC3107771 | biostudies-literature
| S-EPMC7349934 | biostudies-literature
| S-EPMC11749362 | biostudies-literature
| S-EPMC10880497 | biostudies-literature
| S-EPMC9212066 | biostudies-literature
| S-EPMC4468565 | biostudies-literature
| S-EPMC2953695 | biostudies-literature
| S-EPMC145319 | biostudies-literature
| S-EPMC7341470 | biostudies-literature
| S-EPMC4039538 | biostudies-literature